Physiotherapy in Patients Hospitalized Due to Pneumonia.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02515565 |
Recruitment Status : Unknown
Verified July 2018 by Marie Carmen Valenza, Universidad de Granada.
Recruitment status was: Recruiting
First Posted : August 4, 2015
Last Update Posted : July 12, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pneumonia | Drug: cephalosporin with or without erythromycin Other: Physiotherapy program | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia |
Actual Study Start Date : | September 2015 |
Actual Primary Completion Date : | April 2018 |
Estimated Study Completion Date : | July 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Experimental group
Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
|
Other: Physiotherapy program
The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
Other Names:
|
Control group
Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
|
Drug: cephalosporin with or without erythromycin
Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
Other Name: Standard medical treatment |
- Muscle strength [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days ]Quadriceps strength will be assessed with a portable dynamometer. The test will be performed as previously reported.
- Exercise capacity [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days ]Five times sit to stand test (5STS) will be used to assess exercise capacity, 5STS is a simple assessment tool that is feasible in all healthcare settings, and may be a rapid method of assessing changes in exercise capacity in COPD and screening for poor physical functioning individuals.
- Respiratory function [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days ]Spirometry is regarded as the gold standard measure of respiratory function. Spirometry will be performed according to the American Thoracic Society (ATS) criteria.
- Dyspnea perception [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days ]Dyspnea perception will be assessed with Borg modified scale. Patients will classify their breathlessness between 0 and 10.
- Quality of life [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days. ]EuroQol-5D (EQ-5D) will be used to assess quality of life. EQ-5D is a generic questionnaire and consists of two parts, the EQ-5D Visual analogue scale (VAS) and the EQ-5D index. The EQ-5D VAS consists on a vertical rating scale from 0 to 100 (0 = death/worst possible health state and 100 = best possible health state). The EQ-5D index is a five-item questionnaire (mobility, self-care, usual activity, pain/discomfort and anxiety/depression). Each item has three levels: no problem, some problem and severe problem.
- Functionality [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days. ]The London Chest Activity of Daily Living (LCADL) is a valid tool that is validated to measure breathlessness during daily activities. It is a 15-item questionnaire divided in 4 domains: self-care (4 items), domestic (6 items) physical activity (2 items) and leisure (3 items).
- Fatigue [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days. ]Fatigue will be assessed with the Fatigue Severity Scale (FSS). The FSS is a nine-item instrument designed to assess fatigue as a symptom of a variety of different chronic conditions and disorders. The scale addresses fatigue's effects on daily functioning, querying its relationship to motivation, physical activity, work, family, and social life, and asking respondents to rate the ease with which they are fatigued and the degree to which the symptom poses a problem for them.
- Mood [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days. ]Mood in these patients will be measured by the Hospital Anxiety and Depression Scale.
- Dependency levels [ Time Frame: Baseline ]Dependency levels will be evaluated with the Functional Independence Measure (FIM). It is an 18-item, 7-level scale developed to uniformly assess severity of patient disability and medical rehabilitation functional outcome.
- Comorbidities [ Time Frame: Baseline ]Charlson Comorbidity Index will be used to assess the comorbidities of the patients, it is a simple and valid method of estimating risk of death from comorbid disease. It contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions. Each condition is assigned with a score of 1, 2, 3 or 6 depending on the risk of dying associated with this condition.
- Nutritional status [ Time Frame: Baseline ]Nutritional status was evaluated with Mini nutritional assessment (MNA) test, that is validated to provide a single, rapid assessment of nutritional status in elderly patients in outpatient clinics, hospitals, and nursing homes. The MNA test is composed of simple measurements and brief questions that can be completed in about 10 min.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of pneumonia.
- No contraindication of physiotherapy.
- Signed written consent.
- Medical approval for inclusion.
Exclusion Criteria:
- Contraindications of physiotherapy.
- Neurological, orthopedic or heart disease.
- Prosthetic devices in lower limbs.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02515565
Contact: Marie Carmen Valenza, PhD | 958 248035 | cvalenza@ugr.es | |
Contact: Marie Carmen Valenza, PhD | cvalenza@ugr.es |
Spain | |
Faculty of Health Sciences. University of Granada. | Recruiting |
Granada, Spain, 18071 | |
Contact: M. Carmen, Ph, MD 958 248035 | |
Principal Investigator: M. Carmen Valenza, Ph, MD |
Principal Investigator: | Marie Carmen Valenza, PhD | Universidad de Granada |
Responsible Party: | Marie Carmen Valenza, PhD, Universidad de Granada |
ClinicalTrials.gov Identifier: | NCT02515565 |
Other Study ID Numbers: |
DF0057UG |
First Posted: | August 4, 2015 Key Record Dates |
Last Update Posted: | July 12, 2018 |
Last Verified: | July 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
pneumonia Exacerbation physiotherapy hospitalization |
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Erythromycin Erythromycin Estolate Erythromycin Ethylsuccinate Erythromycin stearate |
Cephalosporins Anti-Bacterial Agents Anti-Infective Agents Gastrointestinal Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |